Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol

K C Bible1, S A Boerner, K Kirkland

  • 1Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.

Insights

Researchers developed a flavopiridol-resistant ovarian cancer cell line. Resistance to flavopiridol and cisplatin is linked to reduced drug accumulation, not altered cell cycle proteins.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Flavopiridol, a cyclin-dependent kinase inhibitor, shows antineoplastic activity.
  • Mechanisms of resistance to flavopiridol are not well understood.
  • Ovarian carcinoma cell lines are crucial for studying drug resistance.

Purpose of the Study:

  • To characterize a spontaneously acquired flavopiridol-resistant ovarian carcinoma cell line.
  • To investigate the mechanisms underlying resistance to flavopiridol and cisplatin.
  • To identify potential alterations in drug accumulation or cell cycle regulation.

Main Methods:

  • Cytogenetic analysis and spectral karyotyping to confirm cell line relatedness.
  • Immunoblotting to assess cell cycle regulatory proteins.
  • Drug sensitivity assays for flavopiridol, cisplatin, and other chemotherapeutics.
  • Mass spectrometry and high-performance liquid chromatography to quantify intracellular drug levels.

Main Results:

  • A high-passage ovarian carcinoma cell line (OV202 hp) developed resistance to flavopiridol (5-fold) and cisplatin (3-fold).
  • OV202 hp cells showed similar levels of cell cycle regulatory proteins as parental cells.
  • Reduced intracellular accumulation of flavopiridol and cisplatin was observed in OV202 hp cells.
  • Resistance was specific, with similar sensitivity to other chemotherapeutic agents.

Conclusions:

  • Spontaneous resistance to flavopiridol and cisplatin in OV202 hp cells is partly due to reduced drug accumulation.
  • Altered drug accumulation may play a significant role in flavopiridol sensitivity.
  • This study provides the first characterization of a flavopiridol-resistant cell line.